“The huge popularity of cannabidiol (CBD), a non-intoxicating component of cannabis, has helped to destigmatize the plant and restore its reputation as an important medicinal herb. But bogus science and inept reporting continue to distort how we understand the benefits and risks of CBD and cannabis,” he asserts.
According to the Little Rock researchers, four-and-a-half mice died from CBD, while somehow one-and-half mice survived.
A recent article by Mike Adams for Forbes, asserts that CBD “could be damaging our livers in the same way as alcohol and other drugs.” This and other conclusions drawn by Adams caused the Henny Pennies of Twitter to insist the sky was falling. (Forbes‘ format does not allow readers to comment, so many took to Twitter to vent their anger.)
Of Mice and Men
However, merely six rodents received this dose. “One doesn’t need an advanced degree in science or math to recognize that something is amiss. Seventy-five percent of six equals 4.5,” he sniffs.
The study of 839 people was completed between August 2020 and February 2021.
The CBD industry has grown since the legalization of hemp, but many questions remain. Many people who ingest CBD products — such as oil or gummies — say it helps ease anxiety and certain pains.
CBD, short for cannabidiol, comes from the cannabis plant. It is one of two most commonly known compounds of cannabis (marijuana), the other being delta-9-tetrahydrocannabinol (THC). It’s the THC that is associated with a “high,” not CBD.
Investigators report to FDA no evidence of liver toxicity in 839 adults consuming oral CBD
Dave Bartkowiak Jr. , Digital Managing Editor
In March 2019, the Michigan Marijuana Regulatory Agency (MRA) and the Michigan Department of Agriculture and Rural Development (MDARD) issued joint guidance for CBD and industrial hemp:
The study, conducted by a team from clinical research company Validcare, aims to help the FDA to determine how to appropriately regulate CBD products.
Michigan’s guidance on CBD and industrial hemp
From the Marijuana Regulatory Agency:
“Congressional leadership asked ValidCare almost 18 months ago to engage industry help collect safety data for FDA. We understand the significance, importance and immediate need for CBD safety research for the FDA, industry and the US consumer. This first of its kind, industry led, multi-branded study required trust, collaboration, operational excellence, innovation, and resilience. It demonstrates the incredible potential for decentralized clinical research to increase participant access and accelerate results – even during the most challenging times” said Patrick McCarthy, CEO of Validcare. “We are excited for our principal investigators to continue, expand and report out on this foundational work in the next few months. Once completed, safety results of this study will be shared with participating brands and FDA. The investigators also plan to publish in a peer reviewed journal.”
Note, the study cited in the article was very small with children under physician care but if you are a liver patient it is a cautionary note if you are considering CBD oil. We are not aware of any research that would suggest using it more broadly but consult your doctor.
We support health writers who wish to spread their work to a wider audience. This article was submitted by Natalie Shae.
Because CBD oil is not considered a drug, it can be a common additive in many products. This includes e-cigarettes (vape oil), lotions and various herbal supplements. It has also been shown to relieve symptoms of different disorders like epilepsy, anxiety and multiple sclerosis.